SCHEMBL26075173

SCHEMBL26075173

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)c(C)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.42
▸ PDE10A Q9Y233 6/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ LMNA P02545 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ DHODH Q02127 3/20 0.40
▸ CHRNA7 P36544 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ PLA2G2A P14555 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ TP53 P04637 3/20 0.39
▸ THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075148 0.91 PDE10A (0.43) SCN9APDE10AKDM4ELMNAALDH1A1
SCHEMBL26075184 0.90 LMNA (0.39) SCN9APDE10AKDM4ELMNAALDH1A1
SCHEMBL26075142 0.90 PDE10A (0.39) SCN9APDE10AKDM4ELMNAALDH1A1
SCHEMBL26075179 0.89 KDM4E (0.47) PDE10AKDM4ELMNAALDH1A1RAB9A
SCHEMBL26075988 0.88 PDE10A (0.45) SCN9APDE10AKDM4ELMNAALDH1A1
SCHEMBL23579612 0.87 DHODH (0.57) PDE10AKDM4ELMNAALDH1A1RAB9A
SCHEMBL29997055 0.87 DHODH (0.57) PDE10AKDM4ELMNAALDH1A1RAB9A
SCHEMBL26075130 0.85 HMOX1 (0.43) SCN9APDE10AKDM4ELMNAALDH1A1
SCHEMBL26075139 0.84 PDE10A (0.42) SCN9APDE10AKDM4ELMNAALDH1A1
SCHEMBL26075168 0.84 PDE10A (0.46) SCN9APDE10AKDM4ELMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD SCN9A 1399/4885PDE10A 3462/4885KDM4E 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback